Found: 11
Select item for more details and to access through your institution.
Effect Size and Blinding in Lumateperone Trial-Reply.
- Published in:
- 2020
- By:
- Publication type:
- letter
Efficacy and Safety of Lumateperone for Treatment of Schizophrenia: A Randomized Clinical Trial.
- Published in:
- 2020
- By:
- Publication type:
- journal article
CL 284,846, a novel sedative-hypnotic: Evaluation of its metabolites for pharmacological activity in vitro and in vivo.
- Published in:
- Drug Development Research, 1994, v. 33, n. 1, p. 39, doi. 10.1002/ddr.430330107
- By:
- Publication type:
- Article
Behavioral characterization of Co 134444 (3α-hydroxy-21-(1'-imidazolyl)-3β-methoxymethyl-5α-pregnan-20-one), a novel sedative-hypnotic neuroactive steroid.
- Published in:
- Psychopharmacology, 2001, v. 155, n. 3, p. 285, doi. 10.1007/s002130100695
- By:
- Publication type:
- Article
Pharmacological evaluation of a modified conflict procedure: punished drinking in non-water-deprived rats.
- Published in:
- Psychopharmacology, 1999, v. 145, n. 3, p. 333, doi. 10.1007/s002130051066
- By:
- Publication type:
- Article
Effects of AMPA receptor antagonists on dopamine-mediated behaviors in mice.
- Published in:
- Psychopharmacology, 1998, v. 136, n. 2, p. 123, doi. 10.1007/s002130050547
- By:
- Publication type:
- Article
LONG-TERM SAFETY OF LUMATEPERONE (ITI-007): METABOLIC EFFECTS IN AÂ 1-YEAR STUDY.
- Published in:
- Schizophrenia Bulletin, 2020, v. 46, p. S214, doi. 10.1093/schbul/sbaa030.517
- By:
- Publication type:
- Article
LUMATEPERONE IN THE TREATMENT OF SCHIZOPHRENIA: EVALUATION OF EXTRAPYRAMIDAL AND MOTOR SYMPTOMS IN 4 LATE-PHASE CLINICAL TRIALS.
- Published in:
- Schizophrenia Bulletin, 2020, v. 46, p. S310, doi. 10.1093/schbul/sbaa029.765
- By:
- Publication type:
- Article
The Effects of Food on the Pharmacokinetics of a Formulated ACP-103 Tablet in Healthy Volunteers.
- Published in:
- Journal of Clinical Pharmacology, 2007, v. 47, n. 7, p. 915, doi. 10.1177/0091270007299361
- By:
- Publication type:
- Article
Pharmacologic profile of ITI-333: a novel molecule for treatment of substance use disorders.
- Published in:
- Psychopharmacology, 2024, v. 241, n. 7, p. 1477, doi. 10.1007/s00213-024-06578-w
- By:
- Publication type:
- Article
Adjunctive lumateperone (ITI‐007) in the treatment of bipolar depression: Results from a randomized placebo‐controlled clinical trial.
- Published in:
- Bipolar Disorders, 2023, v. 25, n. 6, p. 478, doi. 10.1111/bdi.13310
- By:
- Publication type:
- Article